Multicenter Study to Evaluate Safety of Fresolimumab in Adults With Moderate-to-severe Osteogenesis Imperfecta
Latest Information Update: 10 Oct 2024
Price :
$35 *
At a glance
- Drugs Fresolimumab (Primary)
- Indications Osteogenesis imperfecta
- Focus Adverse reactions
- 05 Jul 2022 Status changed from active, no longer recruiting to completed.
- 01 Apr 2022 Results evaluating whetheriIncreased TGF-beta signaling is a driver pathogenic mechanism in OI and anti-TGF-beta therapy could be a potential disease-specific therapy, published in the Journal of Clinical Investigation
- 25 Mar 2022 Status changed from recruiting to active, no longer recruiting.